Cite
ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
MLA
Bochicchio, Maria Teresa, et al. “ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.” International Journal of Molecular Sciences, vol. 25, no. 1, Jan. 2024, p. 118. EBSCOhost, https://doi.org/10.3390/ijms25010118.
APA
Bochicchio, M. T., Marconi, G., Baldazzi, C., Bandini, L., Ruggieri, F., Lucchesi, A., Agostinelli, C., Sabattini, E., Orsatti, A., Ferrari, A., Capirossi, G., Servili, C., Ghelli Luserna di Rorà, A., Martinelli, G., Simonetti, G., & Rosti, G. (2024). ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. International Journal of Molecular Sciences, 25(1), 118. https://doi.org/10.3390/ijms25010118
Chicago
Bochicchio, Maria Teresa, Giovanni Marconi, Carmen Baldazzi, Lorenza Bandini, Francesca Ruggieri, Alessandro Lucchesi, Claudio Agostinelli, et al. 2024. “ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.” International Journal of Molecular Sciences 25 (1): 118. doi:10.3390/ijms25010118.